Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449565 | 0.95 | LMNA (0.46) | LMNACTRB1TSHRFASNNAAA | |
| SCHEMBL12781985 | 0.89 | LMNA (0.43) | LMNACTRB1TSHRFASNNAAA | |
| SCHEMBL13449577 | 0.88 | BCHE (0.45) | LMNACTRB1NAAAPTPN1CDC25B | |
| SCHEMBL16689647 | 0.83 | BCHE (0.46) | LMNACTRB1TSHRFASNNAAA | |
| SCHEMBL17320856 | 0.83 | BCHE (0.46) | LMNAPTPN1CDC25BBCHEACHE | |
| SCHEMBL21243992 | 0.81 | BCHE (0.50) | LMNACTRB1NAAAPTPN1CDC25B | |
| SCHEMBL18521909 | 0.81 | BCHE (0.50) | LMNACTRB1NAAAPTPN1CDC25B | |
| SCHEMBL10177102 | 0.81 | BCHE (0.50) | LMNACTRB1NAAAPTPN1CDC25B | |
| SCHEMBL10328076 | 0.81 | BCHE (0.50) | LMNACTRB1NAAAPTPN1CDC25B | |
| SCHEMBL12264790 | 0.79 | CTRB1 (0.51) | CTRB1FASNPLA2G6PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253622-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253622-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | LMNA 1609/4885CTRB1 2104/4885TSHR 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.